Head and neck squamous cell carcinoma (HNSCC) is the sixth commonest cancer worldwide. For the past 20 years, head and neck cancer has been associated with 5-year survival rate of 50%. Traditional risk-factors for HNSCC patients have included alcohol consumption and tobacco use. More recently, however, the incidence of HPV-related HNSCC is increasing, in line with the overall rise in the incidence of malignancies associated with HPV infection. In recent years, numerous approaches have shown that the immune system can be ...

GO TO STUDY

Stem cell transplantation from a matched sibling or unrelated donor (allo-SCT) is the only curative therapy for many children and adults with blood cancer. However allo-SCT remains associated with a number of life-threatening side effects, the most serious of which is ‘graft-versus-host disease’ (GvHD). This complication occurs when donor immune cells (the ‘graft’) see the patient’s healthy skin, gut or liver (the ‘host’) as foreign and attacks them. Patients currently receive a combination of drugs and antibodies to prevent GvHD. ...

GO TO STUDY

Any patient suspected of having surgically resectable clear cell renal cell carcinoma (ccRCC) (M0/M1) is suitable for screening for WIRE. The study will provide participants with exposure to novel agents as monotherapy and in combination during the period of time between the decision to undergo surgery and resection. This period of time is 4 weeks due to UK cancer targets, during which patients would otherwise remain untreated. The aim of WIRE is to determine if the novel agents will deliver ...

GO TO STUDY

The Champion AF study is designed to determine if left atrial appendage closure with the WATCHMAN FLX Device is a reasonable alternative to Direct Oral Anticoagulant (NOACs) in patients with non-valvular atrial fibrillation. Patients in this study will be randomized to either receive the WATCHMAN FLX Device or a course of NOACs patients will be assessed over a period of up to 5 years.

GO TO STUDY

Acute Lymphoblastic Leukaemia (ALL) is the commonest cancer of children and young adults with over 400 cases diagnosed each year in the UK. While over 90% of children with ALL are cured, some people’s disease is harder to treat than others. ALLTogether1 investigates whether treatment can be reduced for children with the highest chance of cure, and whether the addition of new drugs improves the chance of cure for those whose disease is most likely to relapse. In the UK, ...

GO TO STUDY

Inhibitor development is the most serious treatment-related complication of replacement coagulation factor VIII (FVIII) therapy for patients with haemophilia A. Immune tolerance induction (ITI), which involves intensive treatment with plasma-derived (pdFVIII) or recombinant FVIII (rFVIII), is the only clinically proven strategy for eradication of inhibitors. The bispecific antibody emicizumab is approved for use in patients with and without inhibitors to prevent bleeding but does not eliminate inhibitors. MOTIVATE aims to capture different approaches to the treatment and management of patients ...

GO TO STUDY

Around 3,300 people are diagnosed with soft tissue sarcoma (STS) each year in the UK, and a significant proportion of STS diagnoses are in people aged under 30 years. STS can arise from various tissue types and is comprised of over 50 tumour types. Although STS is treated with a combination of surgery, radiotherapy and chemotherapy, the prognosis is relatively poor with a five-year survival rate of 54%. There is a an unmet need for further treatment modalities in STS. ...

GO TO STUDY

Sudden unexpected death in epilepsy (SUDEP) is a tragic complication of uncontrolled epilepsy, occurring when no other cause of death can be found. Every year between 5 and 9 in 1000 people suffering from epilepsy die from SUDEP; over 40 years up to 12% of patients with active uncontrolled epilepsy may die. In 2008, the NIH National Institute for Neurological Disorders and Stroke (NINDS) convened a workshop to assess current SUDEP knowledge and to make recommendations. The group concluded ...

GO TO STUDY

PPMI2.0 is a broad program, expanding the goals of the original PPMI study that was started in 2010 and has recruited 424 patients with Parkinson's disease (PD), 196 healthy controls, 600 patients with genetic mutations linked to PD, and 65 prodromal participants. The PPMI study has made substantial progresses in PD research with more than 170 publications and 2 million downloads of PPMI data for research purposes worldwide. However, there is a consensus that a new PPMI cohort is ...

GO TO STUDY

Up to 10% of strokes occur in patients aged under 55 years (“young stroke”) causing a large numbers of years lost to ill-health and premature death. More worryingly, the number of new cases of young stroke (“incidence”) appears to be increasing in recent decades in high-income countries.Reasons for this apparent increase are unclear. One explanation is that the observed increase in new cases coincided with the changes in the burden of treatable vascular risk factors among young adults, such as high ...

GO TO STUDY